Natural Capsules Share Price | Natural Capsules Stock Screener
NATCAPSUQ
Pharmaceuticals
Share Price NSE
₹152.45
▼
-0.89 (-0.58%)
Share Price BSE
₹155.00
▲
0.50 (0.32%)
As of July 3, 2026, the Natural Capsules share price (NSE: NATCAPSUQ) is ₹152.45 on NSE and ₹155.00 on BSE, down 0.58% from the previous close, with shares trading between ₹151.90 and ₹154.50, and a 52-week range of ₹143.57–₹278.00.
Analyse NATCAPSUQ share price charts and track historical price performance.
Use the Natural Capsules stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Natural Capsules Market Cap
₹158.55 Cr.
NATCAPSUQ P/E Ratio (TTM)
-6.54
Natural Capsules P/B Ratio
0.73
EPS (TTM)
₹-23.84
Dividend Yield
-
Debt to Equity
0.49
NATCAPSUQ 52 Week High
₹278.00
Natural Capsules 52 Week Low
₹143.57
Operating Margin
2.00%
Profit Margin
-8.47%
NATCAPSUQ Revenue (TTM)
₹59.00
EBITDA
₹2.00
Net Income
₹-5.00
Total Assets
₹424.00
Total Equity
₹222.00
Natural Capsules Share Price Chart
Screen Natural Capsules share price with an interactive chart. Analyse NATCAPSUQ price trends and volatility across different timeframes.
Natural Capsules Company Profile - Fundamental Screener
Screen Natural Capsules company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NATCAPSUQ shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE936B01015
Natural Capsules Balance Sheet Screener
Screen NATCAPSUQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total Assets | 424 | 419 | 377 | 289 | 164 | 97 | 75 | 73 | 71 |
| Current Assets | 137 | 130 | 124 | 102 | 76 | 50 | 38 | 38 | 42 |
| Fixed Assets | 278 | 284 | 103 | 97 | 67 | 38 | 24 | 24 | 22 |
| Liabilities | |||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 57 | 62 | 71 | 74 | 37 | 2 | 1 | 1 | 2 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||||
| Total Equity | 222 | 257 | 229 | 148 | 83 | 62 | 56 | 56 | 54 |
| Share Capital | 10 | 10 | 9 | 9 | 7 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | 211 | 223 | 195 | 114 | 76 | 56 | 49 | 49 | 48 |
Natural Capsules Income Statement Screener - Profit & Revenue Analysis
Screen Natural Capsules income statement and profit fundamentals.
Analyze NATCAPSUQ quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Natural Capsules share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59 | 45 | 46 | 46 | 38 | 41 | 39 | 41 | 44 | 38 | 38 | 38 | 41 | 42 | 44 |
| Expenses | 57 | 41 | 45 | 47 | 40 | 36 | 35 | 37 | 40 | 32 | 32 | 32 | 35 | 33 | 35 |
| EBITDA | 2 | 5 | 1 | -1 | -2 | 5 | 5 | 5 | 4 | 6 | 6 | 6 | 5 | 9 | 9 |
| Operating Profit % | 2.00% | 10.00% | 1.00% | -2.00% | -6.00% | 10.00% | 11.00% | 11.00% | 10.00% | 15.00% | 16.00% | 14.00% | 12.00% | 20.00% | 21.00% |
| Depreciation | 4 | 2 | 4 | 4 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 |
| Interest | 3 | 2 | 3 | 3 | 3 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -5 | 1 | -6 | -8 | -9 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 2 | 7 | 7 |
| Tax | 0 | 0 | -1 | -1 | -2 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Net Profit | -5 | 1 | -6 | -7 | -7 | 1 | 1 | -1 | 0 | 2 | 2 | 2 | 1 | 5 | 5 |
| EPS | -4.82 | 0.13 | -5.40 | -6.76 | -6.88 | 1.31 | 0.65 | -0.60 | 0.10 | 1.85 | 1.96 | 1.67 | 1.29 | 7.02 | 7.43 |
Natural Capsules Cash Flow Screener - Liquidity Fundamentals
Screen NATCAPSUQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 27 | -8 | 17 | -1 | 13 | 7 | 2 | 5 |
| Investing Activities | -45 | -73 | -105 | -46 | -16 | -6 | -7 | -1 |
| Financing Activities | 16 | 82 | 88 | 48 | 3 | -1 | 4 | -4 |
| Net Cash Flow | -2 | 1 | 0 | 1 | 0 | 0 | -1 | 1 |
Natural Capsules Shareholding Pattern Screener
See Natural Capsules shareholding pattern with promoter, FII, and DII holdings.
Check Natural Capsules promoter holding and ownership changes for NATCAPSUQ on TickJournal.
| Item | 2026-Mar | 2025-Feb | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.04% | 51.14% | 51.21% | 51.26% | 51.26% | 51.26% | 56.56% | 56.56% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.31% | 0.18% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 33.06% | 32.86% | 33.09% | 33.04% | 32.94% | 32.95% | 34.72% | 35.10% |
| Other Holding | 15.90% | 16.01% | 15.70% | 15.69% | 15.80% | 15.79% | 7.41% | 8.16% |
| Shareholder Count | 8,850 | 9,552 | 9,425 | 9,311 | 9,573 | 9,075 | 10,954 | 10,514 |
Natural Capsules Share Dividend Screener - Share Yield Analysis
Check Natural Capsules dividend history with payout and yield data.
View Natural Capsules dividend details including ex-dates and amounts for NATCAPSUQ stock.
Natural Capsules Stock Index Membership
See which indices include Natural Capsules stock.
Check NATCAPSUQ index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Natural Capsules Market Events Screener - Corporate Actions
Get Natural Capsules corporate actions including splits, bonuses, and buybacks.
Check Natural Capsules stock events that may affect NATCAPSUQ share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.00 /share | 29.27% | ||
| 2026-05-27 | 2026-05-27 | Quarterly Result Announcement | NA | -3.62% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 2.95% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.85% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -0.46% |
| 2025-08-04 | 2025-08-04 | Annual General Meeting | NA | -3.27% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 2.49% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -10.56% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -4.42% |
| 2024-08-23 | 2024-08-23 | Extraordinary General Meeting | NA | -5.93% |
| 2024-07-26 | 2024-07-26 | Annual General Meeting | NA | 9.84% |
| 2023-07-20 | 2023-07-20 | Dividend | ₹ 1.00 /share | -19.69% |
| 2021-11-11 | 2021-11-12 | Rights | 1:2 | 33.36% |
| 2021-07-06 | 2021-07-08 | Dividend | ₹ 1.00 /share | 1.21% |
Natural Capsules Competitors Screener - Peer Comparison
Screen NATCAPSUQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 457,769 | 39.71 | 58,220 | 6.38% | 11,565 | 69.58 |
| Divis Laboratories | 180,691 | 69.89 | 10,560 | 8.73% | 2,520 | 55.41 |
| Torrent Pharmaceuticals | 161,811 | 75.43 | 13,886 | 20.34% | 2,138 | 70.39 |
| Cipla | 117,945 | 30.51 | 29,045 | 2.24% | 3,870 | 66.80 |
| Zydus Life Science | 115,013 | 22.41 | 26,720 | 13.65% | 5,242 | 66.88 |
| Dr Reddys Laboratories | 114,709 | 27.60 | 35,059 | 3.90% | 4,158 | 67.04 |
| Lupin | 113,599 | 21.14 | 27,488 | 19.98% | 5,345 | 71.73 |
| Mankind Pharma | 104,211 | 53.93 | 14,278 | 12.03% | 1,750 | 60.79 |
| Aurobindo Pharma | 93,643 | 26.86 | 33,385 | 3.21% | 3,376 | 70.76 |
| Laurus Labs | 83,284 | 93.55 | 6,868 | 22.01% | 890 | 71.63 |
Natural Capsules Company Announcements - News Screener
Screen NATCAPSUQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-06-26 | Closure of Trading Window | - |
| 2026-06-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-06-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-06-01 | Corrigendum To The Intimation Under Regulation 30(9) Of SEBI (LODR) Regulations 2015 Dated May 27 2026. | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-28 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-27 | Appointment of Company Secretary and Compliance Officer | - |
| 2026-05-27 | Intimation Under Regulation 30(9) Of SEBI (LODR) Regulations 2015. | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-27 | Approved The Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31 2026. | - |
| 2026-05-27 | Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday May 27 2026. | - |
| 2026-05-20 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday May 27 2026 Of The Company. | - |
| 2026-05-07 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-30 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |